You are here

News / Press Statements

Press Statements

Pfizer Statement on Vincristine Sulfate Injection, USP Supply in the United States
Pfizer Statement on Results of Pay Equity Study and Opportunity Parity Among Colleagues Worldwide
TrialSpark and Pfizer collaborating to improve speed and access to clinical trials
Terry Bradshaw and Pfizer Educate Boomers About the Risks of Pneumococcal Pneumonia and the Importance of Vaccination
Catalia Health and Pfizer collaborate to better understand patient journeys using artificial intelligence and via robot wellness coach
Hospira, Inc., Issues A Voluntary Nationwide Recall for one lot of BACTERIOSTATIC WATER for Injection, USP, due to a Potential Lack of Sterility Assurance.
Findings Released from NAXOS, a French Real-World Data Analysis and the Largest Real-World Data Analysis on Oral Anticoagulant Effectiveness and Safety in Europe Among Patients with Non-Valvular Atrial Fibrillation
Pfizer Inc. Issues A Voluntary Nationwide Recall For 2 Lots of RELPAX® (eletriptan hydrobromide) 40 mg Tablets Due to Potential Microbiological Contamination of Non-Sterile Products
Pfizer Statement on Update to XELJANZ® (tofacitinib) Prescribing Information in the United States
Pfizer Responds to the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention’s Vote to Revise the Recommendation for Routine Use of Prevnar 13® for the Prevention of Pneumococcal Disease for Adults 65 Years or Older
Pfizer confirms initiation of EU review of Tofacitinib with interim recommendations
Pfizer Inc. Issues A Voluntary Nationwide Consumer Level Recall of One Lot of ThermaCare® Back Pain Therapy HeatWraps, up to 16HR pain relief, Due To Out of Specification Results for High Cell Temperature
Hospira, Inc. Issues A Voluntary Nationwide Recall of 8.4% Sodium Bicarbonate Injection, USP Due To The Presence of Particulate Matter.
Pfizer Announces Modification To Ongoing Tofacitinib FDA Post-Marketing Requirement Study In Patients With Rheumatoid Arthritis
Pfizer Inc. Issues A Voluntary Nationwide Consumer Level Recall Of Six Lots Of ThermaCare® HeatWraps Due To Leaking Wraps with the Potential For Skin Injuries
Pfizer Provides Transparency On Drug Prices In The U.S. 90 Percent Of Company’s Prices Will Remain Unchanged
Real-World Evidence on Patients Aged 80 and Older Presented From ARISTOPHANES, the Largest Real-World Data Study Evaluating Oral Anticoagulants Among Patients with Non-Valvular Atrial Fibrillation
Data From Phase 2 PALLET Study of IBRANCE® (palbociclib)in Early Breast Cancer to be Presented at San Antonio Breast Cancer Symposium
Pfizer Announces Initiation of Phase 3 Trial of Tofacitinib in Patients with Ankylosing Spondylitis
Terry Bradshaw and Pfizer Encourage Boomers to Understand Their Risk for Pneumococcal Pneumonia and Take Action to Help Prevent It
Pfizer, Inc. Issues A Voluntary Nationwide Recall Of One Lot Of Children’s Advil® Suspension Bubble Gum Flavored 4 FL OZ Bottle
Exact Sciences and Pfizer Enter into U.S. Promotion Agreement for Cologuard®
Important Update on EpiPen® (epinephrine injection, USP) 0.3 mg Auto-Injectors
Bristol-Myers Squibb-Pfizer Alliance ACROPOLIS™ Real-World Data Program Grows to Sample Size of Nearly One Million Lives Worldwide
Important Notice Regarding EpiPen Auto-Injector U.S. Supply
Pfizer Clarifies Incorrect Media Reports Regarding Amsterdam UMC Clinical Trial
Dr. Seng Hing Cheng appointed Chief Scientific Officer of Pfizer Rare Disease Research Unit
Pfizer announces it will defer company’s price increases
Hospira Issues Voluntary Nationwide Recall Of Daptomycin For Injection Lyophilized Powder For Solution, Due to Infusion Reactions
Hospira Issues A Voluntary Nationwide Recall For Two Lots of Naloxone Hydrochloride Injection, USP, in the Carpuject™ Syringe System Due To The Potential Presence of Particulate Matter.
Pfizer Reaches $23.85 Million Settlement Agreement To Resolve Allegations Related To Patient Assistance Charities
Around the World, People Living with Ulcerative Colitis Share Common Perspectives and Experiences
Important Notice Regarding EpiPen auto-injector supply
Dawn Rogers Appointed Executive Vice President of Pfizer Worldwide Human Resources
Hospira Issues A Voluntary Nationwide Recall For Hydromorphone HCL Injection, USP CII Due To The Potential For Empty Or Cracked Glass Vials
Hospira Issues A Voluntary Nationwide Recall For Labetalol Hydrochloride Injection, USP, Due To The Potential Of Cracked Glass At The Rim Surface Of The Vials
Pfizer Teams Up with Sickle Cell Disease Community to Launch New Online Platform
Greenstone Issues Voluntary Nationwide Recall of Diphenoxylate Hydrochloride and Atropine Sulfate Tablets, USP Due to Possible Sub Potent and Super Potent Tablets
Hospira Issues Voluntary Worldwide Recall For Lots of Hydromorphone HCl Injection, USP, CII, (2 mg/mL) 1mg/mL Vial, and Levophed® (Norepinephrine Bitartrate Injection, USP), 4 mg/4 mL (1 mg/mL) Vial, Due to a Lack of Sterility Assurance
Hospira Issues A Voluntary Nationwide Recall For One Lot of Vancomycin Hydrochloride for Injection, USP, 750 mg/vial Due to The Presence of Particulate Matter Within a Single Vial
Pfizer Provides Update on Proposed Epoetin Alfa Biosimilar
Hospira Issues A Voluntary Nationwide Recall For 8.4% Sodium Bicarbonate Injection…
Pfizer Completes Enrollment of Phase 2 Study of Domagrozumab (PF-06252616)in Duchenne Muscular Dystrophy
Hospira Issues a Voluntary Nationwide Recall For One Lot Of 25% Dextrose Injection, USP (Infant) Due To The Presence of Particulate Matter
Pfizer’s Statement On The Misuse Of Our Products In Lethal Injections For Capital Punishment
Pfizer and the National Newspaper Publishers Association Collaborate to Raise Awareness of Sickle Cell Disease and Need for Improved Patient Care
European League Against Rheumatism (EULAR) Includes Janus Kinase (JAK) Inhibitors in Updated Recommendations for the Management of RA
VYNDAQEL® (tafamidis) Receives Approval in Brazil by ANVISA for the Treatment of Transthyretin Familial Amyloid Polyneuropathy
Pfizer Showcases 12 New Data Presentations On Transthyretin Amyloidosis, Increasing Understanding Of A Rare Disease
Hospira Issues A Voluntary Recall For One Lot Of 50% Magnesium Sulfate Injection, USP Due To The Presence Of Particulate
Hospira Issues A Voluntary Recall For One Lot Of Sodium Bicarbonate Injection, USP Due To The Presence Of A Particulate
HOSPIRA ISSUES A VOLUNTARY NATIONWIDE RECALL OF ONE LOT OF MAGNESIUM SULFATE IN WATER FOR INJECTION DUE TO INCORRECT BARCODE LABELING ON THE PRIMARY CONTAINER
Pfizer Joins Broad Effort to Observe National Disability Employment Awareness Month
Pfizer Expands Support for Patients with Gaucher Disease Through New Agreement for ELELYSO
FDA Accepted For Review Pfizer NDA for ADHD Treatment
Pfizer Applauds House of Representatives for Passing the 21st Century Cures Act
Pfizer Wins Jury Verdict in Zoloft Case in Philadelphia
Pfizer Applauds the Committee on Energy and Commerce for Passing the 21st Century Cures Act Today
Pfizer Praises Passage Of New Alabama Legislation
Statement Regarding FDA Advisory Committees’ Vote on CHANTIX®
The Benefits of a Potential Combination with AstraZeneca PLC ("AstraZeneca")
U.S. Appeals Court Upholds Lyrica Patent That Expires On December 30, 2018
Bridget Walsh Appointed Vice President of Federal Government Relations
Pfizer subsidiary Meridian awarded government contract to develop auto-injector medical countermeasure against nerve agent exposure
Pfizer Statement on PhRMA-EFPIA Principles for Responsible Clinical Trial Data Sharing
Pfizer Mourns Loss of Prominent Leader and Respected Board Member
Pfizer Responds to New York Times Article on NIH Policy
Original Statement Provided to New York Times
Pfizer Response To Global Consensus Statement On Menopausal Hormone Therapy
Zithromax (azithromycin) FDA Drug Safety Communication
Pfizer Chairman and Chief Executive Officer Ian Read Issues Statement on White House Meeting
Pfizer Donates Vials of Factor IX to the World Federation of Hemophilia to Help Developing Countries
Findings from the Kronos Early Estrogen Prevention Study (KEEPS), presented today at The North American Menopause Society (NAMS) Annual Meeting in Orlando, Fla.
The U.S. Food and Drug Administration issued a Drug Safety Communication on Revatio®
Pfizer Helpful Answers mourns the loss of actor Lupe Ontiveros
Ongoing Analyses have Helped Re-evaluate Benefit-Risk Profile of Hormone Therapy for Appropriate Menopausal Women
Pfizer Response To Ongoing Evaluation Of Hormone Therapy And Breast Cancer, And What It Means For Menopausal Women Who Have Had A Hysterectomy
Pfizer Joins Innovative Partnership to Eliminate or Control 10 Neglected Tropical Diseases by 2020
Pfizer Statement Responding to Questions on Voluntary Lipitor Contracting Programs
Pfizer applauds U.S. Sens. Pat Leahy (VT) and Charles Grassley (IA) and U.S. Reps. Patrick Meehan (PA) and Linda Sanchez (CA) for introducing the "Counterfeit Drug Penalty Enhancement Act of 2011."
Pfizer announced that the FDA Vaccines and Related Biological Products Advisory Committee (VRBPAC)
Pfizer Responds to Analysis in PLoS One, an Online Publication of the Public Library of Science
Pfizer Statement Regarding Lyrica Epilepsty
Pfizer Receives Complete Response Letter From FDA For Moderate-To-Severe Vasomotor Symptoms (VMS) Indication For Pristiq® (desvenlafaxine) Extended Release Tablets.
Pfizer strongly believes in and supports Chantix as an important treatment option.
Pfizer Inc. has received the European Commission Decision to renew the marketing authorization (MA) for Champix® (varenicline tartrate) for a further five year period for the treatment of smoking cessation in adults.
Pfizer has studied Chantix (varenicline) in a randomized, double-blind, placebo-controlled clinical trial in smokers with certain types of cardiovascular disease.
Pfizer Inc.ýs Alpharma LLC subsidiary has decided to suspend sales in the United States of 3-Nitro® (Roxarsone), a feed medicine used primarily in poultry production.
Pfizer takes patient safety and regulatory reporting obligations very seriously. All post-marketing reports of adverse events are reviewed by Pfizer and reported to regulatory agencies, including FDA.
Pfizer is appalled by the allegations of abuse in Libya. We condemn any misuse of our medicines. Pfizer stopped shipping all products to Libya in February, when sanctions were implemented by the international community. Our thoughts remain with the peopl
New Guidelines Announce Lyrica® (pregabalin) Capsules CV — Pfizer is proud that Lyrica® (pregabalin) capsules CV, which is an FDA approved treatment indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN)
Pfizer is not involved in the film's production
Pfizer Statement on Conducting Clinical Trials in Response to the FDA Letter Dated April 9, 2010

 

 

Online Pfizer Press Kit